Auph short interest.

About Aurinia Pharmaceuticals Stock (TSE:AUP) Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license ...Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Tuesday November 28, 2023. 20 Min Delayed.Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...If you stay in your home long enough, you usually build enough equity that you can sell it for a profit. When you have to sell the property before then or during a downturn in the market, you may need to find out how to short sale a house.

Aug 15, 2022 · Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ... Jun 29, 2023 · Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...

Sep 27, 2023 · Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ... The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value.

AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report Jul, 2023 Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8. Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272. SIC: 2834 - PHARMACEUTICAL PREPARATIONS. State location: A1 | State of Inc.: A0 | …Financials. AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of ...Cash received for interest $ 2,713 $ 528 Cash paid for income taxes $ (277) $ (779) Cash paid for amounts included in the measurement of lease liabilities $ (531) $ (572) Supplemental disclosure of noncash transactions: Finance right-of-use asset obtained in exchange for lease obligations (monoplant) $ 117,622 $ —Mar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ...

Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…

Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short)

Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...Dec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents. Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...The 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover.Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 16,710,000 shares, a growth of 6.8% from the June 30th total of 15,650,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the […]

The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ... Nov 17, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 16.4% in August marketbeat.com - September 17 at 6:15 AM: Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation finance.yahoo.com - September 11 at 9:56 AM AUPH | Aurinia Pharmaceuticals by Finance Ai provides AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report with insider trading history and institutional ownership breakdown.AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on... HRTX 1.3100 (+20.18%) Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.

Finding the right furnished short term rental can be a daunting task. With so many options available, it can be difficult to know which one is best for you. Here are some tips to help you make the right choice when selecting a furnished sho...Global Coverage. Comprehensive ownership data of US Institutions, Mutual Funds, and ETFs targeting equities and bonds in mature, emerging, and frontier markets. Activist Investor 13D Filings. Beneficial Ownership 13G Filings. Institutional Ownership 13F Filings. Insider 3, 4 and 5 Filings.Web

Artal Group S.A. increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the company’s stock after buying an additional 500,000 …WebAurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11. Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired.Aurinia also disclosed that its chief commercial officer will be leaving next …Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million.For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ... Sep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interestInstitutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQTRKA Update - Nothing has changed with TRKA still sitting at well over 120% short interest. When in doubt just zoom out. This drop is expected after the last run-ups and the heavy shorting. Don't let them scare you off they are …

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 8,290,000 shares, a decline of 27.7% from the October 31st total of 11,460,000 shares.Web

AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .Aurinia Pharmaceuticals (NASDAQ: AUPH) is trading ~2.5% higher in the pre-market after Oppenheimer raised its recommendation on the stock to Outperform from Perform. The price target of $31 per ...Aurinia Pharmaceuticals (AUPH) traded ~5% higher pre-market Thursday after the co. raised its outlook and posted better-than-expected Q2 2023 financials. Read more here.586. -18.84. 2023-11-22. NP. PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional This fund is a listed as child fund of BlackRock Inc. and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value.AUPH | Aurinia Pharmaceuticals by Finance Ai provides AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report with insider trading history and institutional ownership breakdown.Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28. Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has said on Monday its collaboration partner Otsuka Pharmaceutical has filed a new drug application in Japan for its drug voclosporin. Voclosporin is a ...Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short)

May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ... The actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ...Are you a smaller woman looking for a new hairstyle? Short haircuts can be a great way to make a bold statement and show off your features. But with so many options available, it can be hard to know which one is right for you.BBBY short interest is up more than 17.5m shares. r/Shortsqueeze • Bed Bath and to infinity and Beyond - Why BBBY is legitimately the closest play to GME & AMCInstagram:https://instagram. crispr stock price todaygold brokeragesqqq dividend datedrug company etfs Jun 16, 2023 · In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ... E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWeb usduday trader robinhood Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... nickel from 1964 Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …WebShort Interest. Most Shorted. Largest Increase. Largest Decrease. ... The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 67.41% …